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Abstract 
 
BACKGROUND & AIMS: Deleted in liver cancer 1 (DLC1), which encodes a Rho GTPase 
activating protein (RhoGAP), is a bona fide tumor suppressor in hepatocellular carcinoma 
(HCC). Underexpression of DLC1 in cancer has been attributed to genomic deletion and 
epigenetic silencing. However, the regulatory mechanism of the tumor suppressive activity of 
DLC1 remains elusive. In this study, we elucidated a novel post-translational modification by 
which the activity of DLC1 is functionally regulated. METHODS: Molecular and 
biochemical approaches were employed to study Akt phosphorylation of DLC1. In vitro and 
in vivo functional assays were performed to elucidate the functional significance of Akt 
phosphorylation of DLC1. RESULTS: Phosphorylation of ectopically expressed and 
endogenous DLC1 was enhanced upon insulin induction or with Akt expression in liver 
cancer cell lines. Conversely, addition of a PI3K/Akt pathway inhibitor or silencing of Akt 
attenuated the phosphorylation level of DLC1. Site-directed mutagenesis was employed to 
replace the serine residue of the consensus Akt substrate motifs of DLC1 with alanine. S567 
of DLC1 was identified as the only target of Akt phosphorylation. S567 is well conserved in 
all DLC family members. DLC2 was phosphorylated by Akt at the corresponding residue. 
Functional assays demonstrated that the S567D phosphomimetic DLC1 mutant lost its 
inhibitory activities in tumorigenesis and metastasis of oncogenically transformed 
hepatoblasts in a mouse model. CONCLUSIONS: This study has revealed a novel 
post-translational modification that functionally deregulates the biological activities of DLC1. 
Phosphorylation of DLC1 and DLC2 by Akt at the conserved residue points to a common 
regulatory mechanism of the DLC tumor suppressor family. 
Keywords: Deleted in liver cancer 1; Akt; phosphorylation; hepatocellular carcinoma 
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Introduction 
  
 Deleted in liver cancer 1 (DLC1) was identified as a putative tumor suppressor in 
hepatocellular carcinoma (HCC) in 19981. Since its identification, accumulating evidence has 
shown that DLC1 is not only involved in HCC, but also in diverse human cancers2. DLC1 is a 
focal adhesion protein and functions as a Rho GTPase activating protein (RhoGAP)3. 
Localization at focal adhesions, interaction with tensin proteins and RhoGAP activity are 
crucial to the tumor suppressor functions of DLC14-8. When ectopically expressed in cancer 
cells, DLC1 inhibits proliferation and induces apoptosis7, 9-12. Furthermore, DLC1 abrogates 
cell motility and functions as a suppressor of metastasis in cancer cells7, 13-15. Conversely, 
depletion of DLC1 in cells enhances growth and motility potential16, 17. Functional data about 
the loss of DLC1 in HCC tumorigenesis using a knockdown approach was recently 
demonstrated in a mouse model18. 
 
 DLC1 is widely expressed in normal human tissues, but it is frequently underexpressed in 
HCC and other cancers. Heterozygous deletion and promoter hypermethylation of DLC1 are 
commonly found in about 30-50% of prostate19, breast20 and liver cancers21, 22. Other 
mechanisms could possibly be involved in the regulation of DLC1 activity in tumor tissues 
with normal expression of DLC1. Indeed, somatic mutations of DLC1 have been recently 
detected in human prostate cancers23. These mutations localize in the focal adhesion targeting 
region and impair the RhoGAP activity of DLC1. Although DLC1 expression has been well 
documented to be regulated at the transcriptional level, a recent study about regulation of the 
activity and compartmentalization of DLC1 by protein kinases has provided evidence that 
DLC1 activity could be regulated by post-translational modification. Activated protein kinase 
C (PKC) and protein kinase D (PKD) stimulate the association between DLC1 and 14-3-3 
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proteins. Enhanced association blocks DLC1 nucleocytoplasmic shuttling and inhibits the 
RhoGAP activity of DLC124. Moreover, identification of the rat homolog of DLC1, 
p122RhoGAP, as a substrate of Akt has provided insights into a potential regulatory pathway 
of DLC125. However, the functional significance Akt phosphorylation of p122RhoGAP and its 
relevance to human DLC1 have not been investigated. The phosphatidylinositol 3-kinase 
(PI3K)/Akt pathway is an important cell survival cascade. An aberrant Akt signaling pathway 
and downstream effectors have been shown to have crucial roles in human cancers26. Here, 
we hypothesized that Akt is involved in the regulation of the tumor suppression activity of 
DLC1 in HCC. In this study, we elucidated the molecular mechanism of Akt phosphorylation 
of DLC1 in liver cancer cells and determined the functional significance of 
hyperphosphorylated DLC1 in oncogenically transduced mouse hepatoblasts. 
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Materials and Methods 
 
Constructs and reagents 
Expression constructs of Myc-tagged wild-type DLC1 (1-1091), deletion mutants (1-292, 
1-595, 1-807, 292-1091, 648-1091, ∆414-432), the RhoGAP mutant (K714E) and GFP-tagged 
DLC2α were constructed as previously described7, 8, 27. DLC1 internal deletion mutants 
(∆292-353, ∆292-646, ∆375-509 and ∆414-432), phospho-defective mutants (S298A, S329A, 
S432A and S567A) and the phosphomimetic mutant (S567D) as well as wild-type DLC2α and 
the DLC2α phospho-defective mutant (S589A) were generated. Wild-type DLC1, S567A and 
S567D fragments were subcloned into the MSCV-PGK-PIG vector harboring a 6×Myc tag at 
the N-terminus18. The full-length Akt1 fragment was amplified from normal human liver 
cDNA. A PCR-based site-directed mutagenesis method was used to generate the 
constitutively active mutant (E17K)28, the kinase dead mutant (K179M) and the 
phospho-defective mutant (AA, T308AS473A). Amplified fragments were cloned into 
pCS+MT and FLAG-pcDNA3.1(+) (Invitrogen, Carlsbad, CA) expression vectors. Primers 
employed in cloning are listed in Supplementary Information, Table 1. Monoclonal 
anti-β-actin, anti-FLAG and anti-vinculin antibodies were from Sigma-Aldrich (St. Louis, 
MO). Recombinant Akt protein, the Akt in vitro kinase assay kit and antibodies against total 
Akt, phospho-Akt (Ser-473) and phospho-Akt substrate (PAS) were from Cell Signaling 
Technology (Danvers, MA). Anti-Myc and anti-DLC1 antibodies were from Santa Cruz 
Biotechnology (Santo Cruz, CA) and BD Biosciences (San Jose, CA), respectively. 
LY294002 was from Calbiochem (San Diego, CA) and insulin was from Novo Nordisk 
(Denmark). 
 
Cell culture 
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The human embryonic kidney cell line, HEK293T, and hepatocellular adenoma cells, 
SK-Hep-1, were purchased from American Type Culture Collection (Manassas, VA), whereas 
the human HCC cell line, SMMC-7721, was obtained from the Shanghai Institute of Cell 
Biology. HEK293T, SMMC-7721 and SK-Hep-1 cells were cultured in DMEM high glucose 
medium supplemented with 10% (v/v) fetal bovine serum, penicillin, and streptomycin at 
37°C in a humidified incubator with 5% CO2 in air. Mouse p53-/-;RasV12 hepatoblasts were 
cultured as previously described18. MSCV-PGK-PIG retroviral constructs of wild-type and 
mutant DLC1 were transfected into PA317 cells for retroviral packaging. Transfection with 
the indicated plasmid was done with Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Viral 
particles were collected from the medium. Mouse p53-/-;RasV12 hepatoblasts were transduced 
by retroviral particles in the presence of polybrene. Stable cell lines were established under 1 
μg/ml puromycin selection for 1-2 weeks. Phosphorylation of DLC1 was induced by 50-100 
nM of insulin for 30 minutes before collecting cells for protein extraction. Inhibition of 
phosphorylation was carried out by pre-treating cells with 10 μM of LY294002 or other 
inhibitors as controls for 1 h before insulin stimulation. 
 
Colony formation assay 
SMMC-7721 cells were seeded at 1×105 per well into 12-well tissue culture plates. One of the 
DLC1 expression vectors (pCS2+MT, DLC1-pCS2+MT, DLC1S567A-pCS2+MT or 
DLC1S567D-pCS2+MT) was co-transfected with 0.2 μg of pcDNA3.1+(neo) into cells. Cells 
were trypsinized and replated in a 1:20 dilution in triplicates one day after transfection. Cells 
were selected in 700 μg/ml of G418 (Merck, Darmstadt, Germany) for three weeks. Colonies 
formed were fixed with 3.7% formaldehyde and stained with crystal violet solution.  
 
Subcutaneous injection and orthotopic liver implantation in nude mice 
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In vivo tumorigenicity of mouse hepatoma p53-/-;RasV12 cells stably transfected with DLC1, 
S567A or S567D was analyzed by injection into nude mice. For these experiments, 1x105 
cells were inoculated into the right flank of 5-week-old female BALB/c nude mice. Four 
injections were performed for each group. Tumor size was monitored twice a week for 14 
days. Tumor volume was estimated according to the following formula: volume = 1/2 (largest 
diameter) × (smallest diameter)2. Tumors formed were resected two weeks after subcutaneous 
injection for orthotopic liver implantation. The tumors were cut into 1-2 mm3 cubes then 
implanted in liver lobes of the nude mice as previously described29. Four implantations were 
performed per cell line. All animals were sacrificed and examined three weeks after 
implantation. The in vivo tumor formation was detected by bioluminescence. D-luciferin 
(Xenogen, Hopkinton, MA) at 100 mg per kg of animal was injected intraperitoneally into the 
mice, and bioluminescence was detected by an IVIS 100 Imaging System (Xenogen). The 
experiment was performed according to the Animals (Control of Experiments) Ordinance 
(Hong Kong) and followed the University’s guidelines on animal experimentation. The 
diameter of each tumor formed in livers was taken as a measure of tumor size. Livers and 
lungs were excised and fixed in 10% formalin followed by 75% ethanol before paraffin 
embedding. Five-micrometer-thick paraffin sections were cut and stained with 
hematoxylin-eosin for histological examination. Tumors formed were analyzed histologically 
for the presence of any aggressive features such as an invasive tumor front and venous 
invasion. Lungs of mice were analyzed macroscopically or microscopically for any 
established metastasis.  
 
Protein extraction, co-immunoprecipitation and western blotting 
Experimental details of protein lysis, co-immunoprecipitation and western blotting have been 
previously described27. Ectopically expressed epitope-tagged proteins were 
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immunoprecipitated from total cell lysates using antibodies against the tagged epitope, and 
the endogenous DLC1 protein was immunoprecipitated by an anti-DLC1 antibody. 
Immunoprecipitated proteins were subjected to western blotting, and phosphorylation signals 
were determined using the PAS antibody (Cell Signaling).  
 
In vitro kinase assay 
The in vitro kinase assay was performed using an Akt kinase assay kit (Cell Signaling 
Technology) according to the manufacturer’s manual with slight modifications. Recombinant 
GST-DLC1 protein was generated by a GST expression system. GST-DLC1 or 
immunoprecipitated Myc-tagged DLC1 was washed twice in 1× kinase buffer (25 mM Tris, 
pH 7.5, 5 mM β-glycerophosphate, 2 mM DTT, 0.1 mM Na3VO4, 10 mM MgCl2). In the 
50-ml reaction, 0.2-0.5 mg of DLC1 protein was incubated with 0.2 mM ATP with or without 
0.2 mg of GST-Akt1 at 30°C for 30 minutes. The reaction was stopped by adding 10 ml 6× 
protein loading dye and boiling for five minutes. The phosphorylation signal was detected 
using the PAS antibody for western blotting. A known Akt substrate, recombinant GSK, was 
used as a positive control. 
 
Statistical analysis 
Student’s t-test analysis by GraphPad Prism 5.02 (San Diego, California, USA) was used to 
determine the difference between the results of experimental groups with those of the control. 
A P-value less than 0.05 was regarded as statistically significant. Mean and standard deviation 
(s.d.) of each group were calculated and shown. 
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Results 
 
DLC1 is a substrate of Akt 
 ScanProsite protein sequence analysis of DLC1 revealed the presence of three 
characteristic phospho-Akt substrate (PAS) motifs, (R/K)XRXX(S*/T*) (R: arginine; K: 
lysine; S* and T*: phosphorylated serine and threonine; and X: any amino acid) at amino 
acids 293-298 (RKRSVS*), 324-329 (RTRSLS*) and 562-567 (RLRWHS*) of DLC1 (Figure 
1A). Three potential Akt phosphorylation serine residues, S298, S329 and S567, are all 
localized in the central region of DLC1 and are conserved among human DLC1 and rat 
p122RhoGAP. S329 corresponds to S322 of the rat homolog, which was previously reported 
to be phosphorylated by Akt25. To elucidate whether Akt also phosphorylates human DLC1, 
we employed an antibody against PAS to detect the phosphorylation of DLC1. The 
phosphorylation was detected in ectopically expressed Myc-DLC1 in HEK293T cells. The 
phosphorylation was enhanced by insulin stimulation (Figure 1B) or Akt co-transfection 
(Figure 1C) while dramatically reduced when the cell lysate was treated with alkaline 
phosphatase (Supplementary Figure 1). The phosphorylation of endogenous DLC1 was 
verified in the SK-Hep-1 hepatoadenocarcinoma cell line, in which DLC1 expression is high. 
The phosphorylation was detected in immunoprecipitated endogenous DLC1 (Figure 1D). 
Insulin stimulation enhanced DLC1 phosphorylation, whereas addition of the PI3K inhibitor 
LY294002 reduced the phosphorylation. Depletion of Akt also suppressed phosphorylation of 
DLC1 (Figure 1E). An in vitro kinase assay further demonstrated phosphorylation of DLC1 
by recombinant Akt1 (Figure 1F; Supplementary Figure 2). Basal phosphorylation signal was 
detected in immunoprecipitated DLC1. Presumably, this is due to endogenous Akt activity in 
the cells. 
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Akt phosphorylates DLC1 at S567 
 To identify the Akt-phosphorylated residue(s) in DLC1, a panel of DLC1 deletion 
mutants was examined for the phosphorylation signal (Figure 2A). Loss of the PAS signal in 
the ∆292-646 mutant suggested that the phosphorylated residue(s) was located in amino acids 
292-646 of DLC1 (Figure 2B). Detection of the signal in the ∆292-353 mutant, in which S298 
and S329 were removed, implicated that S567 was the potential Akt-phosphorylated residue. 
In addition, detection of signal in the 400-1091, 450-1091 and 500-1091 mutants but not in 
the 648-1091 mutant further supported that S567 was the phosphorylation target 
(Supplementary Figure 3). Intriguingly, the PAS signal could not be detected in C-terminal 
deletion mutants, such as 1-595, 1-807, 1-878, 1-989, suggesting that an intact START 
domain is required for phosphorylation of DLC1 by Akt (Figure 2C; Supplementary Figure 
3B). However, the functional significance of the START domain in Akt phosphorylation of 
DLC1 remains to be further investigated. Direct phosphorylation of DLC1 by Akt was 
confirmed by the in vitro kinase assay using recombinant Akt1 and GST-DLC1 500-1091 and 
500-878 fusion proteins (Figure 2D). 
 
 In order to validate that S567 is the target of Akt phosphorylation, phospho-defective 
mutants (S298A, S329A, S567A) with an alanine substitution of S298, S329 and S567, 
respectively, were created (Figure 2A). The phosphorylation was completely absent in the 
S567A mutant, whereas a strong signal was detected in wild-type DLC1 as well as in both 
S298A and S329A mutants (Figure 2E). In addition, co-transfection with Akt dramatically 
enhanced the phosphorylation in all DLC1 constructs, with the exception of S567A. 
Consistently, recombinant Akt1 strongly phosphorylated immunoprecipitated Myc-tagged 
DLC1, S298A and S329A, but not S567A (Figure 2F). 
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Akt phosphorylates DLC2 at the corresponding residue to DLC1 S567 
 DLC family members (DLC1, DLC2 and DLC3) are structurally conserved with high 
sequence homology30 (Figure 3A). Sequence analysis also revealed the presence of putative 
PAS motifs in amino acids 253-258 (RARAKS*), 567-572 (RDRRDS*) and 584-589 
(RLRWHS*) of DLC2 and in amino acids 203-208 (RHRNRS*), 556-561 (RERRDS*) and 
563-578 (KLRWHS*) of DLC3. Among all putative PAS motifs, S567 of DLC1 is the only 
putative phosphorylation residue to be conserved in the family. S567 of DLC1 corresponds to 
S589 of DLC2 and S578 of DLC3 (Figure 3A). We found that the phosphorylation was also 
detected in DLC2 and was enhanced when DLC2 was co-transfected with Akt (Figure 3B). 
Substitution of S589 with alanine completely abolished the phosphorylation and suggests that 
Akt phosphorylates DLC2 at the corresponding S589. 
 
DLC1 interacts with Akt 
 Demonstration of Akt phosphorylation of DLC1 prompted us to further investigate 
whether DLC1 interacts with Akt. Co-immunoprecipitation confirmed interaction between 
ectopically expressed DLC1 and Akt (Figure 4A). Apart from wild-type Akt, only the 
constitutively active Akt E17K mutant could robustly interact with DLC1, but the kinase dead 
Akt, K179M, and phospho-defective, T308AS473A (AA), mutant failed to associate with 
DLC1. This result revealed the requirement of Akt kinase activity in DLC1-Akt association. 
In accordance with this finding, DLC1 was only phosphorylated by wild-type and 
constitutively active Akt. Endogenous Akt was shown to interact with Myc-DLC1, and the 
interaction of these proteins was enhanced upon insulin stimulation (Figure 4B). We also 
questioned whether the phosphorylation status of DLC1 would affect its interaction with Akt. 
Our result showed that S567A had largely reduced interaction whereas S567D displayed a 
stronger binding with Akt compared to the wild-type DLC1 (Figure 4C). This suggests that 
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S567 phosphorylation status of DLC1 correlates to its binding with Akt. Another serine 
residue, S432, resides in a pseudo-site with a sequence (KRRNSS*) similar to the consensus 
PAS motif. Substitution of S432 with alanine also did not affect the DLC1-Akt interaction, 
and this further supports the idea that the DLC1-Akt interaction is specifically determined by 
phosphorylation at S567 (Figure 4D). 
 
Akt phosphorylation of DLC1 regulates its growth suppression activity 
 DLC1 has been well documented to inhibit cell growth when ectopically expressed in 
various cancer cell lines7, 23, 31, 32. To determine the functional significance of phosphorylation 
of DLC1 at S567, we performed a colony formation assay using SMMC-7721 cells to 
compare the growth suppression activities of DLC1 with its mutants (Figure 5A). The S567A 
mutant inhibited colony formation as efficiently as wild-type DLC1. Both the RhoGAP 
mutant K714E and the phosphomimetic mutant S567D lost the ability to inhibit colony 
formation. The growth suppression activity of DLC1 was also assessed by colony formation 
assays and proliferation curves in an activated Akt background. These assays revealed that 
wild-type DLC1 lost growth inhibitory activity, whereas the S567A mutant retained its ability 
to suppress HCC cell growth (Supplementary Figure 4). Our findings implicate that 
phosphorylation at S567 by Akt deregulates the activity of DLC1 in suppressing cell growth. 
 
 Recently, functional data about the loss of DLC1 in HCC tumorigenesis using specific 
short-hairpin RNA interference were first demonstrated in a mouse model18. To determine the 
physiological relevance of DLC1 phosphorylation in tumorigenicity, we stably expressed 
DLC1 and its mutants in a mouse p53-null hepatoblast cell line expressing an oncogenic Ras 
(p53-/-;RasV12) labeled with luciferase (Figure 5B). Compared with the control cells, DLC1 
and S567A dramatically suppressed cell growth (Figure 5C) and anchorage-independent 
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growth (Figure 5D). In contrast, S567D displayed largely attenuated growth suppression 
activity when compared to DLC1 and S567A. S567D cells grew faster and formed more and 
bigger colonies. DLC1 has been shown to induce apoptosis in an HCC cell line12. To 
investigate whether Akt phosphorylation affects the apoptosis-inducing activity of DLC1, 
stable clones of DLC1 were subjected to flow cytometry and TUNEL staining 
(Supplementary Figure 5). The data showed a higher percentage of subG1 population and 
more positive TUNEL-stained cells were detected in DLC1 and S567A cells when compared 
with the control and S567D cells. Moreover, wildtype DLC1 was shown to lose its ability to 
induce apoptosis in hepatoma cells with activated Akt background. The stable clones of DLC1 
and its mutants were then injected subcutaneously into nude mice and tested for their in vivo 
tumorigenicity (Figure 5E). Both wild-type DLC1 and the S567A mutant efficiently 
suppressed tumor formation, whereas S567D mutant formed the biggest tumors among all 
experimental groups (Figure 5F).  
 
 Solid tumors excised from subcutaneous injection were subjected to orthotopic liver 
implantation. Three weeks after implantation, luciferase imaging revealed inhibition of tumor 
growth by wild-type DLC1 and the S567A mutant when compared to the control. In contrast, 
the S567D mutant accelerated tumor growth (Figure 6A). In accordance with the luciferase 
signal, wild-type DLC1 and the S567A mutant formed smaller tumors whereas S567D formed 
the largest tumors among all groups (Figure 6B). Wild-type DLC1 and the S567A mutant 
delayed tumor onset in vivo. Because of the enormous tumor formation, animals of S567D 
group were the first to die (Figure 6C). Examination of the livers revealed that tumor 
microsatellite formation was found in two out of four mice from the S567D group in contrast 
to only a single focus of microsatellite formation found in just one mouse each in the vector 
and wild-type groups (Figure 6D and 6F). Distant metastases in the lungs were found in all 
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mice from the S567D group and in none of the mice in the wild-type group (Figure 6E and 
6F). In the S567D group, large foci of lung metastasis were found in three mice, and a total of 
10 large foci were observed. Although lung metastases were found in two mice in each of the 
vector and S567A groups, large foci were found in two mice, and a total of 12 foci were 
formed in the vector group. However, in two mice of the S567A group, mostly 
micrometastases were observed, and only two large foci were found in the whole group. 
Collectively, the incidence of lung metastases and aggressive features were reduced in tumors 
derived from the wild-type and S567A groups. Our data revealed that both wild-type and 
S567A mutant DLC1 efficiently suppressed the metastatic potentials of hepatoma cells but 
that the S567D mutant lost the inhibitory ability to suppress metastasis.  
 
 
Discussion 
 
  In this study, we have shown that Akt is a novel regulator of DLC1. Activated Akt 
interacted with and phosphorylated DLC1 at S567. Hyper-phosphorylated DLC1 lost its 
tumor suppressive activity in tumorigenesis and metastasis (Figure 7). A previous study 
reported that Akt phosphorylates rat DLC1, p122RhoGAP, at S32225. However, our data 
showed that Akt did not phosphorylate S329 (which corresponds to S322 of p122RhoGAP), 
but that instead, S567 is the major target of Akt. This reflects differential regulatory signaling 
pathways in rat and human DLC1 or in different cell types. In spite of the differential 
regulation between orthologs, our data showed that Akt also phosphorylated the 
corresponding residue in another human DLC family member, DLC2. Although we did not 
provide evidence about Akt phosphorylation of DLC3, conservation of S567 of DLC1 with 
the corresponding residues in DLC2 and DLC3 implies that DLC3 could also be 
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phosphorylated by Akt. Our findings here have provided the first evidence about the 
importance of S567 and point to a common regulatory mechanism in the DLC family.  
 
 All DLC family members share a similar structural organization, including the presence 
of a sterile alpha motif (SAM) domain at the amino-terminus as well as RhoGAP and 
steroidogenic acute regulatory (StAR)-related lipid transfer (START) domains at the 
carboxyl-terminus. The central region between the SAM and RhoGAP domains is less 
conserved among family members and has no specialized structural domain30. Nevertheless, 
the central region has been shown to be responsible for focal adhesion localization and 
interaction with tensins, events which are crucial to the growth suppression activity5, 6, 8, 27. 
The central region of DLC1 has been shown to be phosphorylated by PKC/PKD24. 
Phosphorylation of DLC1 by PKC and PKD enhances its interaction with the 14-3-3 adaptor 
protein. Association with 14-3-3 inhibits the RhoGAP activity and facilitates the cytosolic 
retention of DLC1. Our findings have further implicated the importance of the central region 
of DLC1 for post-translational modification that is crucial for its tumor suppressive capacities. 
The present study has shown that phosphorylation of DLC1 at S567 by Akt reduced the ability 
of DLC1 to inhibit the cell growth of both human HCC cells in vitro and mouse hepatoblasts 
in vivo as well as the metastasis of the latter. The inhibitory function of DLC1 in cancer cell 
metastasis has been reported in breast cancer cells13. In this study, we demonstrated that 
DLC1 also functions as a negative regulator of mouse hepatoma metastasis.  
 
 In the physiological context, enhanced activation of Akt through phosphorylation at S473 
in clinical HCC samples has been detected and correlated with poorer overall survival33. Apart 
from down-regulation of DLC1 expression observed in about 50% of cancers21, 22, enhanced 
phosphorylation levels of DLC1 could be an indicator for functionally deregulated DLC1 in 
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cases with normal expression level of DLC1. Elevated expression levels and hyperactivation 
of Akt have been observed in many human cancers34, and DLC1 has been shown to be 
functionally involved in diverse human cancers. In this regard, deregulation of DLC1 tumor 
suppressor functions by enhanced activation of Akt is implicated in a broad spectrum of 
human cancers. In order to validate the altered Akt/DLC1 signaling pathway in human 
cancerous tissues, generation of specific phospho-DLC1 (S567) antibody will be an 
indispensable tool. Due to the failure in generating the phospho-DLC1 after several attempts, 
the study of the enhanced phosphorylation of DLC1 in human cancers cannot be 
accomplished at present and awaits investigation in future.   
 
 Focal adhesion localization and RhoGAP activity have been demonstrated to have crucial 
roles in the tumor suppression activity of DLC15, 6, 8, 11, 23, 35. However, our data revealed that 
the focal adhesion localization and RhoGAP activity of DLC1 were not affected by 
phosphorylation by Akt. Immunofluorescence staining revealed that, similar to wild-type 
DLC1, both S567A and S567D mutants displayed punctate patterns at the boundary that 
perfectly co-localized with vinculin in SMMC-7721 cells (Supplementary Figure 6A). 
RhoGAP activity of DLC1 could be reflected by its ability to inhibit RhoA activity and stress 
fiber formation7, 23, 35, 36. Upon transient transfection, wild-type DLC1 inhibited 
serum-induced stress fiber formation in SMMC-7721 cells, but the K714E RhoGAP mutant 
lost the ability to suppress stress fiber formation (Supplementary Figure 6B). Both S567A and 
S567D inhibited stress fiber formation as efficiently as wild-type DLC1. Consistently, a 
rhotekin pull-down assay showed that RhoA activity was inhibited in all stable HCC clones of 
wild-type and mutant DLC1 (Supplementary Figure 6C). Collectively, in spite of the 
deregulation of DLC1 tumor suppression functions by Akt phosphorylation, the RhoGAP 
activity of DLC1 was not affected. Indeed, mediation of growth suppression activity via 
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RhoGAP-independent mechanisms has been implicated in non-small cell lung cancer 
(NSCLC) cells15. Expression of a GAP-deficient DLC1 mutant also inhibited 
anchorage-independent growth and invasion of NSCLC cells, although to a lesser extent than 
the wild-type DLC1 did. Abrogation of the tumor suppressive activity of DLC1 by Akt 
phosphorylation through a RhoGAP-independent pathway suggests that DLC1 is potentially 
involved in other, undefined mechanisms, which await further investigation.  
 
 
Figure Legends  
 
Figure 1. Akt phosphorylates DLC1. (A) Schematic representation of three putative 
phospho-Akt substrate motifs and potential Akt phosphorylation residues, S298, S329 and 
S567, in the central region of DLC1. (B) Detection of phosphorylation signal of DLC1. Under 
insulin stimulation, Myc-DLC1 expressed in HEK293T cells was immunoprecipitated (IP) by 
Myc antibody and detected by phospho-Akt substrate (PAS) antibody. The signal detected was 
enhanced upon insulin stimulation. (C) Positive signal detected by PAS antibody was also 
enhanced when DLC1 was co-expressed with Akt. (D) Endogenous DLC1 in SK-Hep-1 cells 
was immunoprecipitated by DLC1 antibody and subjected to western blotting using PAS 
antibody. Phosphorylation was elevated upon insulin stimulation and was reduced by 
LY294002 treatment. (E) Depletion of Akt by siRNA suppressed phosphorylation of DLC1. 
(F) Immunoprecipitated Myc-DLC1 was phosphorylated by recombinant Akt1 in an in vitro 
kinase assay.  
 
Figure 2. Akt phosphorylates DLC1 at S567. (A) Schematic diagram of DLC1 and its mutants. 
(B) Different Myc-DLC1 constructs expressed in HEK293T cells were immunoprecipitated 
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by Myc antibody and detected by PAS antibody. Loss of PAS signal in the ∆292-646 mutant 
and positive signal detected in the ∆292-353 mutant implicated that S567 may be the main 
phosphorylation target. (C) C-terminal deletion mutants of DLC1 with intact PAS motif(s) 
could not be phosphorylated by Akt. (D) In vitro kinase assay showing purified GST-DLC1 
fusion proteins (500-1091, 500-878) incubated with or without recombinant Akt1 in the 
presence of ATP. The phosphorylation was detected using PAS antibody by western blotting. 
Akt could directly phosphorylate DLC1. (E) HEK293T cells co-transfected with DLC1 or 
phospho-defective mutants (S298A, S329A and S567A) and FLAG-Akt were subjected to 
immunoprecipitation by Myc antibody and immunoblotted with PAS antibody. PAS signal 
was completely lost in the S567A mutant. (F) Recombinant Akt1 could only phosphorylate 
immunoprecipitated S298A and S329A, but not S567A.  
 
Figure 3. Akt phosphorylates another DLC family member, DLC2 (A) Putative PAS motifs in 
DLC family members. Potential phosphorylation residues are marked by asterisks. Only S567 
of DLC1, corresponding to S589 of DLC2 and S578 of DLC3, was conserved among the 
family. (B) Wild-type DLC2 (WT) and its phospho-defective mutant (S589A) were expressed 
in HEK293T cells with or without FLAG-Akt. Cell lysates were immunoprecipitated with 
Myc antibody and immunoblotting with PAS antibody. PAS signal detected in the 
immunoprecipitated Myc-DLC2 was enhanced in the presence of Akt. The PAS signal was 
completely lost in the S589A mutant.  
 
Figure 4. Association between DLC1 and Akt. (A) Akt activity is essential for the interaction 
between DLC1 and Akt. HEK293T cells were co-transfected with different forms of 
FLAG-Akt (WT: wild-type; E17K: constitutively active; K179M: kinase-dead; AA: 
phospho-defective) and Myc-DLC1. Cell lysates was subjected to immunoprecipitation. 
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DLC1 could only interact with the wild-type and constitutive active Akt, but not the 
kinase-dead and phospho-defective Akt. PAS could only be detected in DLC1 that associated 
with Akt. (B) Insulin stimulation enhanced the interaction between DLC1 and Akt. (C) 
Myc-DLC1 constructs (WT, S567A and S567D) were transfected with FLAG-Akt into 
HEK293 cells and cells were subjected to immunoprecipitation. The S567A mutant showed a 
weaker interaction with Akt than wild-type DLC1. The S567D mutant had the strongest 
interaction with Akt. (D) Another serine residue, S432, resides in a pseudo-site with the 
sequence KRRNSS*, which is similar to the consensus Akt substrate motif. The Myc-DLC1 
mutant S432A was expressed in HEK293 cells with FLAG-Akt and examined for its 
interaction with Akt. 
 
Figure 5. Akt phosphorylation attenuated growth suppression activities of DLC1. (A) 
Different DLC1 constructs were expressed in SMMC-7721 cells and grown in selective 
medium for two weeks. Numbers of colonies formed were counted. (B) Stable expression of 
DLC1 in p53-/-;RasV12 hepatoma cells was confirmed by western blot analysis using Myc 
antibody. (C) Growth curves of p53-/-;RasV12 hepatoma cells expressing different forms of 
DLC1. S567D had a faster proliferation rate than DLC1 and S567A. (D) DLC1 and S567A 
formed significantly fewer colonies than the vector control in a soft agar assay. (E) DLC1 
stable clones were inoculated into nude mice, and tumor size was measured three times a 
week. (F) Tumors were excised and weighed at the end of experiments. H&E staining of 
representative tumors is shown. Mean ± s.d. of values were calculated and shown. Data were 
analyzed by Student’s t-test, and P<0.05 was considered as statistically significant. 
 
Figure 6. Metastasis inhibitory activity of DLC1 was abrogated by phosphorylation by Akt. 
(A) Orthotopic liver implantation of hepatoma cells stably expressing DLC1. 
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Bioluminescence images were detected by IVIS 100 Imaging System (Xenogen). (B) Livers 
were resected and the size of the tumor formed was measured and plotted. Mean ± s.d. of 
values were calculated and shown. Data were analyzed by Student’s t-test, and P<0.05 was 
considered as statistically significant. (C) Survival of mice with orthotopic liver implantation 
of tumors derived from hepatoma cells stably expressing DLC1 (n = 8 for each group). 
Asterisks indicate that DLC1 and S567A were significantly different from vector control. (D) 
Tumors formed in liver of the wild-type DLC1 group displayed bulging growth fronts. 
Microsatellite formation (indicated by arrows) detected in S567D tumors. (E) Lungs were 
excised and examined for tumor nodules formation. (F) Summary of aggressive features of 
the orthotopic liver-implanted tumors. 
 
Figure 7. Activated Akt pathway induces phosphorylation of DLC family members. Activated 
Akt phosphorylates DLC1 at S567. This putative phosphorylated serine residue is well 
conserved in the DLC family. S567 of DLC1 corresponds to S589 of DLC2 and S578 of 
DLC3. DLC2 was shown to be phosphorylated at S589 as well. Hyper-phosphorylated DLC1 
lost its tumor suppression activities in tumorigenesis and metastasis of mouse p53-/-;RasV12 
hepatoma cells. 
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Supplementary Materials and Methods 
 
Colony formation assay 
PLC cells of 1×105 were seeded per well of 12-well tissue culture plates. DLC1 expression 
vector (pCS2+MT, DLC1-pCS2+MT, DLC1S567A-pCS2+MT or DLC1S567D-pCS2+MT) 
was co-transfected with FLAG-Akt into cells. Cells were trypsinized and replated in a 1:20 
dilution in triplicates one day after transfection. Cells were selected in 900 μg/ml of G418 
(Merck, Darmstadt, Germany) for 3 weeks. Colonies formed were fixed with 3.7% 
formaldehyde and stained with crystal violet solution. 
 
Establishment of stable mouse p53-/-; Akt hepatoblast expressing DLC1 and its mutants 
MSCV-PGK-PIG retroviral constructs of wild-type and mutant DLC1 were transfected into 
PA317 cells for retroviral packaging. Viral particles were collected from the medium. Mouse 
p53-/-; Akt hepatoblast cell were transduced by retroviral particles in presence of polybrene1. 
Stable cell lines were established under 1ug/ml puromycin selection for 1-2 weeks. 
 
Proliferation curve 
Cells were seeded at 1×104 cells per well of 12-well culture plates in triplicates and 
maintained in growth medium. Cell numbers were counted by using a hematocytometer at 
24-hr intervals for 5 days. Mean values and standard deviations of the triplicates were 
calculated and plotted against time. 
 
Flow cytometry 
Mouse p53-/-; RasV12 and p53-/-; Akt hepatoma cells stably expressing DLC1 and its 
mutants were fixed with 0.5% paraformaldehyde in PBS and permeabilized with 70% ethanol. 
Cells were then stained with propidium iodide and DNA profile of cell populations was 
determined by flow cytometry and analyzed by WINMDI version 2.9. Apoptotic cells were 
defined as cells in subG1 population. Percentage of cells in subG1 phase in each stable clone 
was determined. Data represent the mean of triplicates and standard deviation was calculated. 
 
Terminal decxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay 
Cells with at 1×104 were seeded on coverslip in 12-well culture plate and cultured for 2 days. 
The cells on coverslip were fixed with 4% paraformaldehyde. TUNEL assay (in situ cell death 
detection kit, TMR red) was then performed according to the manufacturer’s manual (Roche).   
 
Immunofluorescence staining  
To reveal the subcellular localization of Myc- and FLAG-DLC1 in SMMC-7721 cells, 
transfected cells were fixed with paraformaldehyde and permeabilized with Triton-X-100. 
DLC1 was stained with either Myc (Santa Cruz Biotechnology) or FLAG (Sigma-Aldrich) 
antibodies. The endogenous vinculin was stained by vinculin antibody (Sigma). Stress fibers 
formation was induced by serum induction for an hour and the F-actin was visualized by 
tetramethylrhodamine B isothiocyanate (TRITC)-labeled phalloidin (Sigma). Subsequent to 
primary antibody incubation, cells were washed and stained with flourochrome-conjugated 
secondary antibodies. Images were captured by a Leica Q550CW fluorescence microscope 
(Leica, Wetzler, Germany). Experimental details have been described elsewhere16. 
  
Rhotekin pull down assay 
The RhoA activity levels in DLC1 transiently transfected cells and in DLC1 stable hepatoma 
cells were detected using a Rho Activation Assay Biochem Kit (Cytoskeleton) as described 
elsewhere16. Cells were serum-starved for 24 hours and stimulated with lysophosphatidic 
acid. Cell lysate was then collected and subjected to GST-RBD pull-down. The pull-down 
samples were subjected to SDS-PAGE analysis and the level of active RhoA was revealed by 
RhoA antibody.  
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Supplementary Table 1 Primers used for cloning expression plasmids. 
Primer Sequence (5’-3’) 
DLC1-NcoI354-F GTCCCCATGGTGGAGCAGAACTTTAAGAAC 
DLC1-NcoI647-F GTCCCCATGGTGCAGCGCACAGGACAACCG 
DLC1-EcoRI-400F TAGAATTCGAACTGGAGGACGGGAAGC 
DLC1-EcoRI-450F TAGAATTCGCTCTACTCCAGTTCAGGG 
DLC1-EcoRI-500F TAGAATTCGCTGGACTCGGTCTCTCCC 
DLC1-878-SalIR TAGTCGACATTACCCAGGTGCCCGA 
DLC1-374-R TTCAGGGATGTAGAACACCG 
DLC1-510-F CCAAAACAGATACACCTGG 
DLC1-873-R GAGTGCTTCCAGAGTGAGG 
DLC1-S298A-F GAGGAGCGTTGCCAACTCCACGCAGACC 
DLC1-S298A-R GGTCTGCGT GGAGTTGGCAACGCTCCTC 
DLC1-S329A-F CCCGGAGCCTCGCTGCGTGCAACAAGC 
DLC1-S329A-R GCTTGTTGCACGCAGCGAGGCTCCGGG 
DLC1-S432A-F CTGAAGAGACGCAATTCTGCCAGCTCCATGAGC 
DLC1-S432A-R GCTCATGGAGCTGGCAGAATTGCGTCTCTTCAG 
DLC1-S567A-F CTGAGATGGCACGCTTTCCAGAGCTCAC 
DLC1-S567A-R GTGAGCTCTGGAAAGCGTGCCATCTCAG 
DLC1-S567D-F CTGAGATGGCACGATTTCCAGAGCTCAC 
DLC1-S567D-R GTGAGCTCTGGAAATCGTGCCATCTCAG 
DLC2-S589A-F GACTCCGATGGAACGCTTTCCAGCTGTCG 
DLC2-S589A-R CGACAGCTGGAAAGCGTTCCATCGGAGTC 
DLC2-313ERI-F CAGAATTCGCCGCCACCTG 
DLC2-stopSalI-R TGGTCGACTCAGATTTTAGTTTCTGG 
BHI-Akt1-F GTGGATCCATGAGCGACGTGGCTATTGTGAAGG 
ERI-Akt1-R GGAATTCTCAGGCCGTGCCGCTGGCCGAG 
Akt1-E17K-F CAAACGAGGGAAGTACATCAAGACC 
Akt1-E17K-R GGTCTTGATGTACTTCCCTCGTTTG 
Akt1-K179M-F CTACTACGCCATGATGATCCTCAAG 
Akt1-K179M-R CTTGAGGATCATCATGGCGTAGTAG 
Akt1-T308A-F GCCACCATGAAGGCCTTTTGCGGCAC 
Akt1-T308A-R GTGCCGCAAAAGGCCTTCATGGTGGC 
Akt1-S473A-F CTTCCCCCAGTTCGCCTACTCGGCCAGCG 
Akt1-S473A-R CGCTGGCCGAGTAGG CGAACTGGGGGAAG 
Supplementary Figure Legends 
 
Supplementary Figure 1. Phosphorylation signal of DLC1 was detected by PAS antibody. 
Lysates of HEK293 cells transiently transfected with Myc-DLC1 and with insulin stimulation 
were treated with shrimp alkaline phosphatase (SAP). Cell lysates were then 
immunoprecipitated with Myc antibody and immunoblotted with PAS antibody. Positive band 
detected by PAS antibody decreased dramatically upon SAP treatment indicates that the 
positive band detected by PAS is phosphorylation signal. 
 
Supplementary Figure 2. Positive control of the in vitro kinase assay. Recombinant GSK 
was incubated with ATP with or without GST-Akt. The reaction mix was then subjected to 
western blotting using PAS and phospho-GSK3β antibodies. GSK was highly phosphorylated 
with the presence of GST-Akt. PAS antibody detected positive signal in both Akt and GSK 
while phospho-GSK3β antibody only detect phosphorylation signal in GSK. 
 
Supplementary Figure 3. Mapping of Akt phosphorylation residue(s) of DLC1. (A) 
Detection of PAS signal in the N-terminal deletion mutants, 400-1091, 450-1091 and 
500-1091 suggests that phosphorylation residue(s) resides in the C-terminal of DLC1. (B) 
Positive signal was only detected in 292-1091 mutant. Loss of PAS signal in 1-595 in which 
S567 was retained suggested that the presence of C-terminal half of DLC1 was essential for 
Akt phosphorylation o f DLC1.  
 
Supplementary Figure 4. Growth suppression activity of DLC1 was suppressed in cells with 
high Akt background. (A) Colony formation assay. DLC1 constructs were co-expressed with 
Akt in PLC cells and grown in selective medium for 2 weeks. Numbers of colonies formed 
were counted. (B) Stable expression of DLC1 in p53-/-; Akt hepatoma cells. DLC1 expression 
in stable clones was detected by Western blot analysis using Myc antibody. (C) Growth curves. 
wildtype DLC1 lost its growth inhibitory activity while the phospho-defective mutant S567A 
retained its growth inhibitory activity. 
 
Supplementary Figure 5. Akt phosphorylation inhibited the activity of DLC1 to induce 
apoptosis. DNA profile of mouse (A) p53-/-;RasV12 and (C) p53-/-;Akt hepatoma cells stably 
expressing DLC1 and its mutants were determined by flow cytometry. Percentage of cells in 
subG1 phase was determined. Wild-type DLC1 and S567A mutant significantly induced 
subG1 population when compared with vector control and S567D mutant in p53-/-;RasV12 
cells. The apoptosis-inducing ability of wild-type DLC1 was reduced in p53-/-;Akt cells. (B 
and D) Apoptosis was measured by TUNEL staining. The number of TUNEL-stanined cells 
was significantly higher in p53-/-;RasV12 cells expressing wild-type DLC1 and S567A. In 
p53-/-;Akt cells, the number of TUNEL-stained cells in wild-type DLC1 expressing cells was 
similar to that of the vector control and S567D mutant. Data was analyzed by student’s t-test 
and P<0.05 was considered as statistically significant. 
 
Supplementary Figure 6. Focal adhesion localization and RhoGAP activity of DLC1 were 
not affected by S567 phosphorylation. (A) Focal adhesion localization of DLC1 and its 
mutants. SMMC-7721 cells were seeded on coverslips and transfected with different FLAG- 
DLC1 constructs (WT, S567A and S567D). The cells were fixed and co-stained with FLAG 
antibody (green), vinculin antibody (red) and DAPI (blue). Vinculin is used as a marker for 
focal adhesions while DAPI stained with nucleus. All wild-type DLC1, S567A and S567D 
co-localized with vinculin at focal adhesions. (B) Stress fiber inhibition assays of wild-type 
DLC1, S567A and S567D mutants. SMMC-7721 cells transfected with Myc-DLC1 constructs 
were induced by serum for an hour. The cells were fixed and immunofluorescence staining 
was performed. Cells were co-stained with Myc antibody (green), TRITC-phalloidin (red) and 
DAPI (blue) followed by fluorochrome-conjugated secondary antibodies. The asterisks denote 
the DLC1-transfected cells. Scale bar = 10 μm. (C) Active RhoA level in stable DLC1 mouse 
hepatoma cells. Cells were serum-starved for 24 hours and stimulated with lysophosphatidic 
acid. Cell lysate was then collected and subjected to GST-RBD pull-down. The pull-down 
samples were subjected to SDS-PAGE analysis and the level of active RhoA was revealed by 
RhoA antibody. 
 
 
 
 
 






